Congress Organization Committee
(Source: Leukemia Research)
Source: Leukemia Research - October 1, 2018 Category: Hematology Source Type: research
Scientific Program
(Source: Leukemia Research)
Source: Leukemia Research - October 1, 2018 Category: Hematology Source Type: research
Speaker Biographies
(Source: Leukemia Research)
Source: Leukemia Research - October 1, 2018 Category: Hematology Source Type: research
Speaker Presentations
(Source: Leukemia Research)
Source: Leukemia Research - October 1, 2018 Category: Hematology Source Type: research
Oral Presentations
(Source: Leukemia Research)
Source: Leukemia Research - October 1, 2018 Category: Hematology Source Type: research
Poster Presentations
(Source: Leukemia Research)
Source: Leukemia Research - October 1, 2018 Category: Hematology Source Type: research
Author index
(Source: Leukemia Research)
Source: Leukemia Research - October 1, 2018 Category: Hematology Source Type: research
Editorial Board
(Source: Leukemia Research)
Source: Leukemia Research - October 1, 2018 Category: Hematology Source Type: research
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy
Imatinib is the most commonly used drug in chronic myeloid leukemia (CML) patients worldwide. [1] Frontline treatment of newly diagnosed patients with imatinib 400 mg daily determined a 10-year survival rate around 82-83% [2], close to that of the general population [3]. In early 2017 a generic formulation of imatinib was introduced in the Italian market and patients switched from branded (i.e. Glivec®, Novartis) to the generic one upon requirement by regi onal health authorities. (Source: Leukemia Research)
Source: Leukemia Research - October 1, 2018 Category: Hematology Authors: Massimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, Maria Cristina Miggiano, Marco Danini, Claudia Minotto, Davide Griguolo, Luciana Marin, Luca Frison, Fabio D ’Amore, Marco Basso, Roberto Sartori, Martina Tinelli, Manuela Stulle, Stefania Fortuna, Source Type: research
An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder which has very poor overall survival, particularly relapsed and refractory AML [1]. The development of tumor-associated antigen-directed cytotoxic agents has opened a new door to improving treatment outcomes in these patients [2]. CD33 antigen is detected on blasts of over 90% of AML patients, making it a highly promising candidate for targeted therapy for AML [3 –6]. (Source: Leukemia Research)
Source: Leukemia Research - October 1, 2018 Category: Hematology Authors: Yimamu Maimaitili, Aki Inase, Yoshiharu Miyata, Akihito Kitao, Yu Mizutani, Seiji Kakiuchi, Yohei Shimono, Yasuyuki Saito, Takashi Sonoki, Hironobu Minami, Hiroshi Matsuoka Tags: Research paper Source Type: research
TFG-RARA: A novel fusion gene in acute promyelocytic leukemia that is responsive to all-trans retinoic acid
Acute promyelocytic leukemia (APL) is classically characterized by the promyelocytic leukemia-retinoic acid receptor α (PML-RARA) fusion, which is the consequence of t(15;17)(q24;q21) chromosomal translocation [1,2]. In rare instances, RARA had been observed to fuse with other partners such as ZBTB16, NUMA, STAT5B, PRKAR1a, BCOR, FIP1L1, NPM and TBLR1[3–5]. Confirmation of RARA-fusion not only provides informat ion on the responsiveness to all-trans retinoic acid (ATRA) treatment, but also a means to detect minimal residual disease (MRD) and monitor disease progression [6,7]. (Source: Leukemia Research)
Source: Leukemia Research - September 29, 2018 Category: Hematology Authors: Mei-Ling Chong, Hao Cheng, Peisong Xu, Hong You, Min Wang, Lu Wang, Hao-Han Ho Tags: Correspondence Source Type: research
Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
In current practice, most patients with chronic myeloid leukemia in chronic phase (CML-CP) receive frontline imatinib mesylate (IM) as a tyrosine kinase inhibitor (TKI) therapy, and approximately 70% of them achieve complete cytogenetic response (CCyR) after 12 months of therapy. However, in the long-term follow-up, about 40% of these patients fail upfront IM treatment due to resistance and/or intolerance [1]. Nearly half of these patients may achieve durable responses with second-generation TKIs (2G-TKIs) (dasatinib, nilotinib, and bosutinib). (Source: Leukemia Research)
Source: Leukemia Research - September 29, 2018 Category: Hematology Authors: Ahmet Emre Eskazan, Mario Tiribelli Source Type: research
Outcomes of Fludarabine, High Dose Cytarabine and Granulocyte-Colony Stimulating Factor (FLAG) as Re-induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow
Acute myeloid leukemia (AML) is primarily a disease of the elderly with the median age at diagnosis being 68 years and nearly 20,000 new cases are diagnosed annually in the United States [1,2]. Patients diagnosed with non-M3 AML fit to receive intensive chemotherapy are treated with induction therapy consisting of an anthracycline and cytarabine [2 –4]. Prognosis of AML is affected by karyotype and molecular aberrations with the majority of patients remaining at risk of relapse. Hematopoietic stem cell transplantation (HSCT) is recommended for patients with adverse prognostic features. (Source: Leukemia Research)
Source: Leukemia Research - September 27, 2018 Category: Hematology Authors: Omer Jamy, Sejong Bae, Luciano J. Costa, Harry P. Erba, Nikolaos Papadantonakis Tags: Research paper Source Type: research
TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is the most frequent cancer in childhood, accounting for 25% of all pediatric malignancy. ALL is a heterogeneous disease that results from the malignant transformation of lymphoid progenitor cells in the bone marrow, blood and extramedullary sites [1]. Multimodal treatment has led to a relatively good prognosis for this disease, with cure rates over 80% [2]. Nonetheless, a significant parcel of patients are refractory to treatment and develop chemo-resistance or relapse after a period of time, leading to treatment failure [3]. (Source: Leukemia Research)
Source: Leukemia Research - September 26, 2018 Category: Hematology Authors: Mar ía Sol Brassesco, Julia Alejandra Pezuk, Maria Angelica Cortez, Karina Bezerra Salomão, Carlos Alberto Scrideli, Luiz Gonzaga Tone Tags: Brief communication Source Type: research
Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy
Waldeyer ’s Ring (WR) is a circular band of lymphoid tissue and mainly consists of nasopharynx, oropharynx, tonsils and tongue base. It is the most common site of non-Hodgkin’s lymphoma (NHL) in the head and neck and accounts for more than 50% of the lesion[1]. The most common histologic subtype of NHL i n WR is diffuse large B cell lymphoma (DLBCL)[2]. Previous reports found that 92% of WR-DLBCL are limited (stage, I/II), and nearly 60% of patients present with tonsil as a primary site [2]. Radiation therapy is commonly used for the treatment of the limited type. (Source: Leukemia Research)
Source: Leukemia Research - September 24, 2018 Category: Hematology Authors: Chunyan Li, Xuejun Ma, Ziqiang Pan, Fangfang Lv, Zuguang Xia, Kai Xue, Qunling Zhang, Dongmei Ji, Junning Cao, Xiaonan Hong, Ye Guo Tags: Research paper Source Type: research
